Medical Oncology

, Volume 28, Issue 4, pp 986–990 | Cite as

{2-[(3-Carboxy-1-oxopropyl) amino]-2-deoxy-d-Glucose} suppresses proliferation and induces apoptosis in the human esophageal cancer cell line

  • Jing WuEmail author
  • Hong Lu
  • Xiangchun Ling
  • Canghai Wang
  • Ji Rui
  • Aiqin Wang
  • Liang Qiao
Original Paper


The aim of this study was to investigate the molecular mechanisms of apoptosis induced by {2-[(3-Carboxy-1-oxopropyl) amino]-2-deoxy-d-Glucose} (COPADG) in the esophageal cancer cell line Eca-109 and to establish a relationship between the rate of apoptosis and Fas and Bcl-2 protein expression. Eca-109 cells were cultured under standard condition. Cell growth was measured by MTT assay. Apoptosis and cell proliferation were determined by flow cytometry. Expressions of apoptosis-regulated genes Fas and Bcl-2 were detected by immunohistochemical methods and image analysis. COPADG dose- and time-dependently inhibited the growth of Eca-109 cells in vitro. Incubation of Eca-109 cells with 40 μmol/l of COPADG for 48 h induced significant apoptosis. After drug treatment, Fas protein expression was increased, while Bcl-2 protein expression was decreased. COPADG is able to induce apoptosis in the esophageal cancer cell line Eca-109. The mechanism of apoptosis in these cells may be related to up-regulation of Fas gene expression and the down-regulation of Bcl-2, which may serve as the experimental evidence for development of new drugs for the non-surgical management of human esophageal cancer.


Esophageal cancer Apoptosis {2-[(3-Carboxy-1-oxopropyl) amino]-2-deoxy-D-Glucose} Fas Bcl-2 


  1. 1.
    Wu J, Lu H, Zhou Y, Qiao L, Ji R, Wang A-Q, et al. Effect of 2-(3-carboxy-1-oxopropyl) amino-2-deoxy-D-glucose on human esophageal cancer cell line. World J Gastroenterol. 2004;10:3380–1.PubMedGoogle Scholar
  2. 2.
    Wu J, Wei K, Wang A-Q, Liu W-M, Xue Q-J, Qiao L. Effects of 2-[(3-carboxy-1-oxoprogy1) amino]-2-deoxy-D-Glucose on human hepatocellular carcinoma cell line. Acta Pharmacol Sin. 2005;26:635–40.PubMedCrossRefGoogle Scholar
  3. 3.
    Zhe Wang, Yan Qiao, Huang Gao-Sheng. Glucosamine and glucosamine hydrochloride induced leukemia cell line K562 differentiation into macrophage. Chin Pharacological Bulletin. 2003;19:290–3.Google Scholar
  4. 4.
    Wang Z, Qiao Y, Huang G-S. Induction of macrophagic differentiation of leukemia cell line K562 by N-acetyl-D-glucosamine. J Fourth Mil Med Uni. 2003;24:46–8.Google Scholar
  5. 5.
    Xie Q, Dai Y, Sun F. The morphology of melanoma induced by glucosamine hydrochloride. J Anhui TCM College. 2002;21:42–4.Google Scholar
  6. 6.
    Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 1997;18:240–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Cohen J. Apoptosis: Mechanisms of life and death in the immune system. J Allergy Clin Immunol. 1999;103:548–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Von Reyher U, Strater J, Kittstein W. Colon carcinoma cells use different mechanisms to escape CD95 mediated apoptosis. Cancer Res. 1998;58:526–34.Google Scholar
  9. 9.
    Nambu Y, Hughes SJ, Rehemtulla A. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 1998;101:1102–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Matsuzaki I, Suzuki H, Kitamura M, Minamiya Y, Kawai H, Ogawa J. Cisplatin induces Fas expression in esophageal cancer cell lines and enhanced cytotoxicity in combination with LAK cells. Oncology. 2000;59:336–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H, Masunaga R, Nagasue N. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res. 1999;5:2464–9.PubMedGoogle Scholar
  12. 12.
    Younes M, Lechago J, Ertan A, Finnie D, Younes A. Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett’s esophagus. Hum Pathol. 2000;31:434–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Kase S, Osaki M, Adachi H, Kaibara N, Ito H. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Int J Oncol. 2002;20:291–7.PubMedGoogle Scholar
  14. 14.
    Sarbia M, Bittinger F, Porschen R. Bcl-2 expression and prognosis in squamous cell carcinoma of the esophagus. Int J Cancer. 1996;69:324–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Raouf AA, Evoy DA, Carton E, Mulligan E, Griffin MM, Reynolds JV. Loss of Bcl-2 expression in Barrett’s dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation. Dis Esophagus. 2003;16:17–23.PubMedCrossRefGoogle Scholar
  16. 16.
    Hsia JY, Chen CY, Hsu CP, Shai SE, Yang SS, Chuang CY, Wang PY, Chen JT. Expression of apoptosis-regulating proteins p53, Bcl-2, and Bax in primary resected esophageal squamous cell carcinoma. Neoplasma. 2001;48:483–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jing Wu
    • 1
    • 2
    Email author
  • Hong Lu
    • 2
  • Xiangchun Ling
    • 1
  • Canghai Wang
    • 1
  • Ji Rui
    • 2
  • Aiqin Wang
    • 3
  • Liang Qiao
    • 2
    • 4
  1. 1.Department of Gastroenterology and HepatologyBeijing Shijitan HospitalBeijingChina
  2. 2.Department of Gastroenterology and HepatologyFirst Teaching Hospital of Lanzhou UniversityLanzhouChina
  3. 3.Lanzhou Institute of Chemical Physics, Chinese Academy of SciencesLanzhouChina
  4. 4.Department of Gastroenterology and Hepatology, Storr Liver Unit, Westmead Millennium InstituteUniversity of Sydney at Westmead HospitalWestmeadAustralia

Personalised recommendations